Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254277 · ClinicalTrials.gov registry record · Phase 1
3BNC117-LS First-in-Human Phase 1 Study
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03254277 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 43 participants.
The verdict
NCT03254277, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.
Interventions
- DRUG Placebo
- DRUG 3BNC117-LS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03254277
The ClinicalTrials.gov registry entry for NCT03254277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03254277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03254277 about?
NCT03254277 is a clinical study titled "3BNC117-LS First-in-Human Phase 1 Study". The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single ad...
What is the current status of trial NCT03254277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2017-09-13. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03254277?
The interventions under investigation include: Placebo (DRUG), 3BNC117-LS (DRUG).
Who is sponsoring clinical trial NCT03254277?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.